An investigation on behalf of investors of Voyager Therapeutics, Inc. (NASDAQ: VYGR) shares over potential securities laws violations by Voyager Therapeutics, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) concerning whether a series of statements by Voyager Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambridge, MA based Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. Voyager Therapeutics, Inc. reported that its annual Total Revenue rose from $7.61 million in 2018 to $104.39 million in 2019, and that its normalized Loss declined from $88.28 million in 2018 to $43.59 million in 2019.

On October 12, 2020, Voyager Therapeutics, Inc. disclosed that it 'has received feedback from the U.S. Food and Drug Administration (FDA) on the Investigational New Drug (IND) submission for VY-HTT01 for the treatment of Huntington's disease.' Specifically, Voyager advised investors that it 'has been notified that the IND was placed on clinical hold pending the resolution of certain chemistry, manufacturing and controls (CMC) matters.'

Shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) declined on October 13, 2020 to $10.90 per share.